United Therapeutics Achieves Historic UKidney Transplant Milestone in Xenotransplantation

United Therapeutics Achieves Milestone in Xenotransplantation with Successful UKidney Transplant

United Therapeutics Corporation reaches a groundbreaking milestone in the field of xenotransplantation by successfully conducting the world's first transplant of its investigational UKidney organ into a living patient. This historic operation, performed on November 25, 2024, at NYU Langone Health, underscores the company's commitment to addressing the critical shortage of transplantable organs. Led by Dr. Robert Montgomery, the surgical team navigates the complexities of this pioneering procedure, which follows a series of successful xenotransplants that include the UHeart and UThymoKidney.

The patient, Towana Looney, a 53-year-old woman from Alabama, faced severe kidney failure after complications from pregnancy. Her previous experience as a kidney donor to her mother made her journey even more poignant, as she struggled to find a compatible donor due to elevated antibody levels. The UKidney, developed by Revivicor, Inc., a subsidiary of United Therapeutics, is derived from a genetically modified pig with ten gene alterations designed to enhance compatibility with human recipients. This innovative approach demonstrates the potential of xenotransplantation to alleviate the organ shortage crisis, as highlighted by the U.S. Renal Data System's report that over 550,000 Americans were dependent on dialysis in 2021.

Martine Rothblatt, Ph.D., CEO of United Therapeutics, emphasizes the significance of this achievement not only for the company but also for the thousands of patients awaiting organ transplants. She expresses gratitude towards the surgical team and Looney's family for their role in this historic event. This successful UKidney transplant represents a pivotal step towards the company's mission of creating an unlimited supply of transplantable organs, providing hope for patients in dire need of life-saving procedures.

In addition to the UKidney transplant, United Therapeutics has made notable advancements in the field of xenotransplantation, having previously completed two UHeart transplants and a UThymoKidney transplant. Each successful procedure builds upon the knowledge and experience gained, reinforcing the potential of genetically engineered organs as viable alternatives for patients facing organ shortages.

As the field of xenotransplantation evolves, United Therapeutics stands at the forefront of innovation, striving to transform the landscape of organ transplantation. The company's commitment to research and development signifies a hopeful future for patients, offering them a second chance at life through groundbreaking medical advancements.